Although the interaction between methylene blue and serotonin reuptake inhibitors/serotonin norepinephrine reuptake inhibitors is well documented, there remains a paucity of literature on identifying patient groups who may be at risk for experiencing this interaction. Here, we report a case of methylene blue and venlafaxine-induced serotonin syndrome in a patient with cancer.
PelgrimsJDe VosFVan den BrandeJ, et al.Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000;82(2):291–294.
2.
NgBKCameronAJ. The role of methylene blue in serotonin syndrome: a systematic review. Psychosomatics. 2010;51(3):194–200.
3.
AjithkumarTParkinsonCShamshadF, et al.Ifosfamide encephalopathy. Clin Oncol (R Coll Radiol). 2007;19(2):108–114.
4.
SzabaturaAHCirroneFHarrisC, et al.An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. J Oncol Pharm Pract. 2015;21(3):188–193.
5.
KupferAAeschlimannCWermuthB, et al.Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet. 1994;343(8900):763–764.
6.
DunkleyEJIsbisterGKSibbrittD, et al.The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96(9):635–642.
